DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Pain Management Clinics Application for Certificate of Exemption
November 1, 2018

Click here for the application to apply for a certificate of exemption as required by Florida’s new controlled substance law (House Bill 21). Continue reading


Annual Report & Long-Range Plan Released for the 2017-2018 Fiscal Year
November 1, 2018

The Annual Report & Long-Range Plan for the 2017-2018 Fiscal Year is now available to view online. Continue reading